Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.

Molecular cancer therapeutics - 1 May 2013

Konecny Gottfried E, Kolarova Teodora, O'Brien Neil A, Winterhoff Boris, Yang Guorong, Qi Jingwei, Qi Zhengdong, Venkatesan Natarajan, Ayala Raul, Luo Tong, Finn Richard S, Kristof Jessica, Galderisi Chad, Porta Diana Graus, Anderson Lee, Shi Michael M, Yovine Alejandro, Slamon Dennis J

Abstract excerpt

The recent identification of activating fibroblast growth factor receptor 2 (FGFR2) mutations in endometrial cancer has generated an opportunity for a novel target-based therapy. Here, we explore the therapeutic potential of 2 FGFR inhibitors, the multikinase inhibitor dovitinib (TKI258) and the more selective FGFR inhibitor NVP-BGJ398 for the treatment of endometrial cancer. We examined the effects of both...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Cell Cycle Checkpoints

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometrial Neoplasms

Share to Inhibitory Concentration 50

Share to Phenylurea Compounds

Share to Quinolones

Share to Receptor, Fibroblast Growth Factor, Type 2

Share to Tumor Burden

Source

Identifiers

PMID: 23443805
DOI: 10.1158/1535-7163.MCT-12-0999

Genes

FGFR2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.PMID 23443805Read ↗

Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells.Semantic proximity Read ↗

Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.Semantic proximity Read ↗

The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.Semantic proximity Read ↗

Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model.Semantic proximity Read ↗

Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53Semantic proximity Read ↗

Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.Semantic proximity Read ↗

PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers.Semantic proximity Read ↗

FGFR2 as a molecular target in endometrial cancer.Semantic proximity Read ↗

The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors.Semantic proximity Read ↗

Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations.Semantic proximity Read ↗

Drug-sensitive FGFR2 mutations in endometrial carcinoma.Semantic proximity Read ↗

Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.